Helus Pharma (HELP), formerly Cybin (CYBN): Scientific Deep Dive for HLP003 and Pipeline Products

Can Deuterated Psychedelics Survive the Cash Cliff to Reach Commercialization?

Executive Summary

The Hook:

Helus Pharma isn’t trying to invent a new mechanism; they are arguably trying to patent-hack a proven one. Their lead asset, HLP003, is a deuterated analog of psilocin (the active metabolite of magic mushrooms, which has a substantially shorter half life than psilocybin). By replacing hydrogen atoms with deuterium, they claim to create a New Chemical Entity (NCE) that mimics the psychedelic efficacy of psilocybin but with optimized pharmacokinetics — specifically, a shorter duration and potentially faster onset than psilocybin, with a longer duration than psilocin. They are essentially betting they can turn a 6-8 hour trip into a more manageable clinic visit, potentially solving the logistical headache that currently plagues psychedelic medicine.